Skip to main content

Lindsay Dudfield, Executive Director and CEO of Jindalee Resources Limited, Executed MOU with POSCO Holdings For Joint Research At McDermitt Lithium Project

JINDALEE RESOURCES LIMITED  (ASX: JRL) (Jindalee, the Company) is an Australian exploration company with Tier 1 lithium deposits in its portfolio in the United States. The Company’s core goals are to discover world-class mineral deposits and generate shareholder wealth. The United States is one of the largest marketplaces for lithium demand, and Jindalee is a leading company committed to help meet future demand. The Company is focussing efforts into developing its McDermitt lithium deposit. Jindalee Resources was listed on the Australian Securities Exchange (ASX) on 11th July 2002 and raised AUD 2.70 million. Now, it is a pure-play United States lithium company. Jindalee’s Projects: In June 2018, the Company acquired McDermitt and Clayton North, two lithium sediment projects in the United States. Both projects are 100% owned by HiTech Minerals Inc., a wholly owned, US-based subsidiary of Jindalee. Several factors attracted the Company’s interest in these projects including: Potenti...
Post a Comment

Roquefort Therapeutics PLC (LSE: ROQ) And Randox Laboratories Strike Exclusive License Agreement For Medical Diagnostics

 Roquefort Therapeutics PLC (LSE: ROQ, OTCQB: ROQAF), a cancer-focused biotechnology company, has made a significant announcement recently. The Company has signed an EXCLUSIVE LICENSING AND ROYALTY AGREEMENT with Randox Laboratories Ltd., a global leader in medical diagnostics. The agreement (“Randox Licence Agreement”) pertains to Roquefort’s Midkine antibody portfolio and is limited to medical diagnostics.

As per the Randox Licence Agreement, Roquefort Therapeutics has granted Randox an exclusive worldwide (except Japan) license to use its Midkine antibodies in medical diagnostics. This license agreement is valid for ten years. The two companies will work together on a combined research programme to identify new cancer diagnostics that will be treatable with Roquefort’s Midkine therapeutics. This collaborative effort aims to leverage the strengths of both companies to develop innovative diagnostic solutions for cancer patients.

The agreement’s commercial terms remain undisclosed. Roquefort Therapeutics estimates a transaction value of over GBP 5 million from the deal over its ten-year term. With its partnership with Randox, Roquefort has validated its strategy of targeting Midkine. A heparin-binding protein found in cancer that forbids tumour cell death and promotes the metastatic spread and abides the treatment. By partnering with Randox, a leading company that produces life-saving diagnostics essential for clinical trials, ROQUEFORT THERAPEUTICS can continue focusing on developing first-in-class oncology drugs.

The Randox Licence Agreement complements the development of the first in class cancer medicine by identifying patients with cancer expressing Midkine.

These patients can benefit from Midkine therapeutics (antibodies or oligonucleotides) and be enrolled in pharmaceutical clinical trials, a core area for Roquefort Therapeutics.

The Company

ROQUEFORT THERAPEUTICS PLC (LSE: ROQ, OTCQB: ROQAF) is a biotech company listed focused on developing innovative drugs in the high-value and rapidly growing field of oncology. The Company is strategically positioning itself to partner with or sell to big pharma after successfully developing first-in-class oncology medicines. Roquefort Therapeutics PLC, listed in March 2021, has acquired Lyramid Pty Ltd., a leader in developing medicines for a new therapeutic target, Midkine. The Company has also recently acquired ONCOGENI LTD., founded by Professor Sir Martin Evans, Nobel Laureate.

Resource Link



Labels

Labels:

Comments

Post a Comment

Popular posts from this blog

VRX Silica Limited Is All Set For The Arrowsmith North Silica Sand Project: Signed Power LOI With ResourcesWA

  VRX SILICA LIMITED   (ASX: VRX) (VRX or Company) has signed a   LETTER OF INTENT (LOI)   with ResourcesWA, a company   SPECIALISING IN ENERGY AND MINING CONSULTING . The LOI aims to explore a potential power supply solution for their Arrowsmith North Silica Sand Project by directly utilising gas from a nearby wellhead. The  OBJECTIVE  of the LOI is to assess the feasibility of setting up a powerhouse equipped with containerised gas reciprocating engines at a nearby gas wellhead location. The powerhouse would be connected to the existing gas plant through a direct offtake and reticulation to the Arrowsmith North site through a dedicated transmission line. ResourcesWA has a team with ample resources and expertise in project development, delivery, and asset management. The LOI provides a detailed proposal description and reflects the parties’ intentions for  SIX MONTHS . The proposal incorporates all design, construction, and operational requiremen...
Post a Comment
Read more

Platina Resources Limited signed a Joint Venture agreement with Chalice Mining for the Mt Narryer Gold Project

  PLATINA RESOURCES LIMITED  (ASX: PGM) (Platina or the Company) is a mineral resource exploration company based in Western Australia. The Company has inked a  JOINT VENTURE AGREEMENT WITH CHALICE MINING LIMITED , a mineral exploration and development company, to operate the Mt Narryer Gold Project. Terms of the Joint Venture Stage 1 earn-in : Initially, Chalice Mining will earn a  51% INTEREST  in the project by investing  AUD 600,000  within two years, which must include at least  AUD 150,000  in the first year Stage 2 earn-in : Chalice Mining can acquire an additional  24% INTEREST  in the project by investing an extra  AUD 1.8 MILLION  within the next two years Platina free cost carry : Once Chalice Mining has obtained a  75% INTEREST  in the Project, Platina Resources Limited will continue to be free cost carried until the Pre-Feasibility Study is completed Contribute & Dilute : After the Pre-Feasibility...
Post a Comment
Read more

Roquefort Therapeutics and CEO Ajan Reginald: An Inspiring Story

Roquefort Therapeutic’s Portfolio The company’s portfolio includes four best-in-class programs, Midkine antibodies, Midkine RNA therapeutics, STAT-6 siRNA and MK cell therapy, built through the acquisition of Lyramid in 2020 and Oncogeni in 2022: Roquefort has two Midkine programs, developed and run by the acquired Lyramid team. Midkine, a heparin-binding protein, has long been known to be important in embryonic development. While barely detectable in healthy adults, Midkine is highly expressed during oncogenesis. MDK hinders the normal immune response to tumours and promotes metastatic spread to other organs, thereby contributing to various levels of cancer progression and reduced patient survival. Roquefort believes its know-how and patent strategy (the combination of the exclusive license and the efforts to patent in-house R&D) have established the entry barrier in targeting MDK. The patent strategy is focused on both the composition of matter patents and method patents for anti...
Post a Comment
Read more